Advertisement

Drug Safety

, Volume 35, Issue 1, pp 45–60 | Cite as

Experiences with Adverse Drug Reaction Reporting by Patients

An 11-Country Survey
  • Florence van HunselEmail author
  • Linda Härmark
  • Shanthi Pal
  • Sten Olsson
  • Kees van Grootheest
Original Research Article

Abstract

Background: Patients are important stakeholders in pharmacovigilance; however, little formal evaluation has been undertaken of existing patient reporting schemes within and outside Europe. If patient reporting is to be recognized as beneficial for pharmacovigilance and further optimized, methodology and best practice must be internationally shared and promoted.

Objective: This study aims to review the methods of patient reporting of adverse drug reactions (ADRs) in 11 countries worldwide and to compare different aspects of their experiences.

Methods: A survey based on telephone interviews, e-mail discussions and field visits of existing practices in consumer and patient reporting of ADRs was performed in the second half of 2010.

Results: The start dates of the patient reporting schemes vary from 1964 (Australia) to 2010 (Norway). The number of patient reports per country varies widely. Most countries would ideally spend more resources on making the public aware of the possibility that patients can report ADRs.

Keywords

Patient Reporting Adverse Drug Reaction Report Reporting Scheme Suspected Adverse Drug Reaction Therapeutic Good Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors are indebted to all the National Pharmacovigilance Centre representatives and the AME Line who participated in this study.

This study was performed as part of the ‘Monitoring Medicines’ project, which is funded by the Seventh Framework Programme (FP-7) of the Research Directorate of the European Commission [grant 223566].

References

  1. 1.
    Raine J. Risk management: a European Regulatory view. In: Mann RM, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: John Wily & Sons Ltd, 2007: 553–8Google Scholar
  2. 2.
    van Grootheest AC. Improving pharmacovigilance and the role of the pharmacist. Groningen: University of Groningen, 2003Google Scholar
  3. 3.
    Moore N, Begaud B. Improving pharmacovigilance in Europe. BMJ 2010; 340: c1694PubMedCrossRefGoogle Scholar
  4. 4.
    The European Commission (EC). The EU pharmacovigilance system [online]. Available from URL: http://ec.europa.eu/health/human-use/pharmacovigilance/index_en.htm.9-2-2011 [Accessed 2011 Mar 18]
  5. 5.
    van Grootheest K, de Jong-van den Berg LTW. Patients’ role in reporting adverse drug reactions. Expert Opin Drug Saf 2004;3(4): 363–8PubMedCrossRefGoogle Scholar
  6. 6.
    Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 2007; 63(2): 148–56PubMedCrossRefGoogle Scholar
  7. 7.
    Herxheimer A, Crombag R, Alves TL. Direct patient reporting of adverse drug reactions: a fifteen-country survey & literature review [online]. Available from URL: http://www.haiweb.org/10052010/10_May_2010_Report_Direct_Patient_Reporting_of_ADRs.pdf [Accessed 2010 Jul 19]
  8. 8.
    Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf 2009; 32(11): 1067–74PubMedCrossRefGoogle Scholar
  9. 9.
    de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf 2008; 31(6): 515–24PubMedCrossRefGoogle Scholar
  10. 10.
    McLernon DJ, Bond CM, Hannaford PC, et al. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf 2010; 33(9): 775–88PubMedCrossRefGoogle Scholar
  11. 11.
    Avery A, Anderson C, Bond C, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess 2011; 15(20): 1–234PubMedGoogle Scholar
  12. 12.
    Watson R. New rules will allow EU patients to report drug concerns directly. BMJ 2010; 341: c5344PubMedCrossRefGoogle Scholar
  13. 13.
    Borg JJ, Aislaitner G, Pirozynski M, et al. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf 2011; 34(3): 187–97PubMedCrossRefGoogle Scholar
  14. 14.
    Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20(2): 109–17PubMedCrossRefGoogle Scholar
  15. 15.
    van Grootheest AC, Passier JL, van Puijenbroek EP. Direct reporting of side effects by the patient: favourable experience in the first year. Ned Tijdschr Geneeskd 2005; 149(10): 529–33PubMedGoogle Scholar
  16. 16.
    The Uppsala Monitoring Centre, Monitoring Medicines Project. Optimizing drug safety monitoring to enhance patient safety and achieve better health outcomes [online]. Available from URL: http://www.monitoringmedicines.org/DynPage.aspx?id=88578&mn1=6646 [Accessed 2011 Mar1]
  17. 17.
    The Uppsala Monitoring Centre. Vigimed [online]. Available from URL: http://who-umc.org/DynPage.aspx?id=101114&mn1=7347&mn2=7252&mn3=7322&mn4=7450 [Accessed 2011 May 25]
  18. 18.
    The Netherlands Pharmacovigilance Centre Lareb. Lareb newsletter number 2 [online]. Available from URL: http://www.lareb.nl/getmedia/d9035f48-f299-45c1-9000-afc85c25a2cf/Lareb_English_Newsletter_2.pdf [Accessed 2011 May 23]
  19. 19.
    Fortnum H, Lee AJ, Rupnik B, et al. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther. Epub 2011 May 18Google Scholar
  20. 20.
    The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). E2B(R3), clinical safety data management: data elements for transmission of individual case safety reports [online]. Available from URL: http://www.ich.org/products/open-consultation/article/e2br3.html [Accessed 2011 Jan 10]
  21. 21.
    International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). MedDRA MSSO: Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization [online]. Available from URL: http://www.meddramsso.com [Accessed 2011 Jan 10]
  22. 22.
    The Uppsala Monitoring Centre. Adverse reaction terminology WHO-ART [online]. Available from URL: http://www.umc-products.com/DynPage.aspx?id=4918 [Accessed 2011 Jan 10]
  23. 23.
    van Hunsel F, van der Welle C, Passier A, et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol 2010; 66(11): 1143–50PubMedCrossRefGoogle Scholar
  24. 24.
    Kunac DL, Harrison-Woolrych M, Tatley MV. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. N Z Med J 2008; 121(1283): 76–89PubMedGoogle Scholar
  25. 25.
    The Medicines and Healthcare products Regulatory Agency (MHRA). Download Drug Analysis Prints (DAPs) [online]. Available from URL: http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/Druganalysisprints/index.htm [Accessed 2011 Jan 10]
  26. 26.
    The Medicines and Healthcare products Regulatory Agency (MHRA). Drug safety update [online]. Available from URL: http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON2031713 [Accessed 2011 Jan 10]
  27. 27.
    European Commission. Volume 9A of the rules governing medicinal products in the European Union: guidelines on pharmacovigilance for medicinal products for human use [online]. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf [Accessed 2011 Feb 21]
  28. 28.
    Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239–45PubMedCrossRefGoogle Scholar
  29. 29.
    The Uppsala Monitoring Centre. Causality assessment of suspected adverse reactions [online]. Available from URL: http://www.who-umc.org/DynPage.aspx?id=22682 [Accessed 2011 Jan 10]
  30. 30.
    CIOMS Working Group IV. Benefit-risk balance for marketed drugs: evaluating safety signals. Geneva: CIOMS Working Group, 1998Google Scholar
  31. 31.
    van Hunsel F, Talsma A, van Puijenbroek E, et al. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf 2010; 20(3): 286–91PubMedCrossRefGoogle Scholar
  32. 32.
    Hazell L, Cornelius V, Shakir S, et al. Patient reporting of adverse drug reactions in the UK: potential signals generated by patients compared to healthcare professionals [abstract]. Pharmacoepidemiol Drug Saf 2010; 19: S97Google Scholar
  33. 33.
    Hazell L, Cornelius V, Shakir S, et al. Patient reporting of ADRs in the UK: how do patient reports affect potential signals generated by healthcare professionals [abstract]? Pharmacoepidemiol Drug Saf 2010; 19: S321Google Scholar
  34. 34.
    Cumber SL, Heffer SJ, Gandhi S, et al. The Yellow Card Scheme: experience of patient reporting of adverse drug reactions 5 years since launch [abstract]. Pharmacoepidemiol Drug Saf 2010; 19: S321Google Scholar
  35. 35.
    Medical Products Agency (MPA). Serious hepatic reactions associated with the dietary supplement Fortodol [online]. Available from URL: http://www.lakemedelsverket.se/english/All-news/NYHETER—2009/Serious-hepatic-reactions-associated-with-the-dietary-supplement-Fortodol [Accessed 2011 Jan 11]
  36. 36.
    Netherlands Pharmacovigilance Centre Lareb. Bijwerkin-gendatabank [online]. Available from URL: http://www.lareb.nl/Databank/Zoek-op-geneesmiddel.aspx [Accessed 2011 Jan 11]
  37. 37.
    Health Canada. Canada vigilance adverse reaction online database [online]. Available from URL: http://www.hcsc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php [Accessed 2011 Jan 11]
  38. 38.
    Moses GM, McGuire TM. Sleep-driving, sleep-eating and sleep-smoking associated with zolpidem: consumers demonstrating their valuable role in pharmacovigilance [abstract]. Drug Saf 2007; 30(10): 167CrossRefGoogle Scholar
  39. 39.
    Hammond IW, Rich DS, Gibbs TG. Effect of consumer reporting on signal detection: using disproportionality analysis. Expert Opin Drug Saf 2007; 6(6): 705–12PubMedCrossRefGoogle Scholar
  40. 40.
    Lorimer S, Cox A, Langford NJ. A patient’s perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. Epub 2011 May 18Google Scholar
  41. 41.
    Ting KN, Stratton-Powell DM, Anderson C. Community pharmacists’ views on adverse drug reactions reporting in Malaysia: a pilot study. Pharm World Sci 2010; 32(3): 339–42PubMedCrossRefGoogle Scholar
  42. 42.
    McLernon DJ, Bond CM, Lee AJ, et al. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiol Drug Saf 2011; 20(5): 523–31PubMedCrossRefGoogle Scholar
  43. 43.
    Anderson C, Krska J, Murphy E, et al. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. Epub 2011 Apr 15Google Scholar
  44. 44.
    Edwards IR, Lindquist M. Social media and networks in pharmacovigilance: boon or bane? Drug Saf 2011; 34(4): 267–71PubMedCrossRefGoogle Scholar
  45. 45.
    Knezevic MZ, Bivolarevic IC, Peric TS, et al. Using Facebook to increase spontaneous reporting of adverse drug reactions. Drug Saf 2011; 34(4): 351–2PubMedCrossRefGoogle Scholar
  46. 46.
    The Medicines and Healthcare products Regulatory Agency (MHRA). Online reporting site for the Yellow Card Scheme [online]. Available from URL: http://yellowcard.mhra.gov.uk/ [Accessed 2011 May 25]
  47. 47.
    Frankenfeld C. “Serious” and “severe” adverse drug reactions need defining [letter]. BMJ 2004; 329(7465): 573PubMedCrossRefGoogle Scholar
  48. 48.
    Anderson C, Gifford A, Avery A, et al. Assessing the usability of methods of public reporting of adverse drug reactions to the UK Yellow Card Scheme. Health Expect. Epub 2011 Apr 27Google Scholar
  49. 49.
    van Hunsel F, Passier A, van Grootheest AC. Comparing patients’ and healthcare professionals’ ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol 2009; 67(5): 558–64PubMedCrossRefGoogle Scholar
  50. 50.
    van Hunsel F, van Puijenbroek E, de Jong-van den Berg L, et al. Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins. Pharmacoepidemiol Drug Saf 2010; 19(1): 26–32PubMedCrossRefGoogle Scholar
  51. 51.
    van Hunsel FPAM, ten Berge EAAM, Borgsteede SD, et al. What motivates patients to report an adverse drug reaction? Ann Pharmacother 2010; 44(5): 936–7PubMedCrossRefGoogle Scholar
  52. 52.
    Ekins-Daukes S, Irvine D, Wise L, et al. The Yellow Card Scheme: evaluation of patient reporting of suspected adverse drug reactions [abstract]. Pharmacoepidemiol Drug Saf 2006; 15: S105Google Scholar
  53. 53.
    Krska J, Taylor J, Avery A. The views of reporters to the UK Yellow Card Scheme on the importance of direct patient reporting [abstract]. Pharmacoepidemiol Drug Saf 2010; 19: S180Google Scholar
  54. 54.
    Krska J, Anderson C, Murphy E, et al. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme. Drug Saf 2011; 34(5): 429–36PubMedCrossRefGoogle Scholar
  55. 55.
    Jansson K, Ekbom Y, Sjölin-Forsberg G. Basic conditions for consumer reporting of adverse drug reactions in Sweden: a pilot study [abstract]. Drug Saf 2006; 29(10): 927CrossRefGoogle Scholar
  56. 56.
    Alshammari TM, Rizwanuddin Ahmad S, Swartz L, et al. Comparison of adverse drug reaction (ADR) reports submitted to the FDA by consumers and healthcare professionals (HCPs) [abstract]. Pharmacoepidemiol Drug Saf 2009; 18: S4Google Scholar
  57. 57.
    Moses G, McGuire T, McEwen J. The Adverse Medicine Events (AME) Line: Australian experience with consumer pharmacovigilance [abstract]. Drug Saf 2008; 31(10): 956Google Scholar
  58. 58.
    Olsson S, Pal SN, Stergachis A, et al. Pharmacovigilance activities in 55 low-and middle-income countries: a questionnaire-based analysis. Drug Saf 2010; 33(8): 689–703PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Florence van Hunsel
    • 1
    • 2
    Email author
  • Linda Härmark
    • 1
    • 2
  • Shanthi Pal
    • 3
  • Sten Olsson
    • 4
  • Kees van Grootheest
    • 1
    • 2
  1. 1.Netherlands Pharmacovigilance Centre Lareb’s-Hertogenboschthe Netherlands
  2. 2.Department of Pharmacy, Pharmacotherapy and Pharmaceutical CareUniversity of GroningenGroningenthe Netherlands
  3. 3.Quality Assurance and Safety of Medicines, World Health OrganizationGenevaSwitzerland
  4. 4.World Health Organization Collaborating Centre for International Drug MonitoringUppsalaSweden

Personalised recommendations